Short answer
Keros Therapeutics, Inc. (KROS) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $40M (up 180.5% year over year) with net income of $14M.
Q3 2026 key financials · XBRL
- Revenue
- $40M
- +180.5% YoY
- Net income
- $14M
- +294.4% YoY · +149.3% QoQ
- Operating margin
- 32.0%
- EPS (diluted)
- $0.72
- +500.0% YoY · +149.7% QoQ
Source: XBRL data from the Keros Therapeutics, Inc. (KROS) Q3 2026 10-Q on SEC EDGAR. USD.
Keros Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $40.0M, up $25.7M YoY from $14.3M, driven by Takeda milestones
- Net income $14.2M vs $7.3M loss YoY, operating margin 32.0% vs negative 107.9%
- Rinvatercept R&D $5.0M, up $3.7M YoY, best-performing pipeline line
- Cash $259.5M; operating cash flow $(20.6)M vs $134.8M YoY
- Cash runway into second half of 2028; inflation, tariffs and capital-market volatility headwinds
Risk Factors
- Regulatory risk: EU Pharma Package could reduce orphan exclusivity from 10 to 9 years, accelerating generic or biosimilar competition
- Financial risk: $259.5 million cash and cash equivalents expected to fund operations into the second half of 2028
- Clinical risk: Cibotercept TROPOS trial terminated after unanticipated pericardial effusion adverse events
- Competitive risk: DMD competition expanded following Sarepta, Avidity Biosciences and Edgewise Therapeutics developments
- Compliance risk: UK clinical-trial amendments effective April 28, 2026 may increase CRO compliance costs and delay trial initiation
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Keros Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.